Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DSN1B6
|
|||
| Drug Name |
TT-00920
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13] | Phase 1 | [1] | |
| Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Preclinical | [1] | ||
| Company |
TransThera Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 9 (PDE9) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Purine metabolism | |||
| Pathway Interaction Database | Regulation of Androgen receptor activity | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of TransThera Biosciences | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.